MergerJun 17, 2026, 04:12 PM
Nano Dimension Updates on Proposed Business Combination with Infinite Epigenetics
AI Summary
Nano Dimension Ltd. issued a press release to provide additional details on its proposed business combination with Infinite Epigenetics, Inc., an AI-powered preventive health and diagnostics company. The company highlighted Infinite's established science, proprietary data, and commercial success in the over $90 billion chronic disease diagnostics market. Nano Dimension also addressed Murchinson Ltd.'s concerns, emphasizing the value creation opportunity, the 20% premium for Nano's cash value, and the retention of contingent value rights for shareholders.
Key Highlights
- Nano Dimension provided additional information on its proposed business combination with Infinite Epigenetics, Inc.
- Infinite Epigenetics is an AI-powered preventive health and diagnostics company with a CLIA-certified methylation laboratory.
- Infinite's proprietary database contains over 120,000 biological samples and has a network of over 7,500 healthcare providers.
- The chronic disease diagnostics market, which Infinite targets, exceeds $90 billion.
- The proposed combination values Nano Dimension at net cash plus a 20% premium.
- Nano Dimension shareholders will retain contingent value rights on Nano's legacy assets.
- Nano Dimension will receive two board seats in the combined company.
- The company is responding to Murchinson Ltd.'s letter regarding the proposed transaction.
Price Impact
More from NNDM